ATE554106T1 - Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung - Google Patents

Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung

Info

Publication number
ATE554106T1
ATE554106T1 AT04815434T AT04815434T ATE554106T1 AT E554106 T1 ATE554106 T1 AT E554106T1 AT 04815434 T AT04815434 T AT 04815434T AT 04815434 T AT04815434 T AT 04815434T AT E554106 T1 ATE554106 T1 AT E554106T1
Authority
AT
Austria
Prior art keywords
antibodies
hpv
subject
strains
proteins
Prior art date
Application number
AT04815434T
Other languages
English (en)
Inventor
Peter Lu
Jonathan Garman
Michael Belmares
Diaz-Sarmiento Chamorro Somoza
Johannes Schweizer
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Application granted granted Critical
Publication of ATE554106T1 publication Critical patent/ATE554106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04815434T 2003-12-23 2004-12-23 Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung ATE554106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53237303P 2003-12-23 2003-12-23
PCT/US2004/043356 WO2005063286A1 (en) 2003-12-23 2004-12-23 Antibodies for oncogenic strains of hpv and methods of their use

Publications (1)

Publication Number Publication Date
ATE554106T1 true ATE554106T1 (de) 2012-05-15

Family

ID=34738792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04815434T ATE554106T1 (de) 2003-12-23 2004-12-23 Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung

Country Status (7)

Country Link
US (5) US7399467B2 (de)
EP (1) EP1708745B1 (de)
JP (1) JP5030594B2 (de)
AT (1) ATE554106T1 (de)
AU (1) AU2004308964B2 (de)
CA (1) CA2551560A1 (de)
WO (1) WO2005063286A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US7312041B2 (en) 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
ATE554106T1 (de) * 2003-12-23 2012-05-15 Arbor Vita Corp Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
EP2024520B1 (de) 2006-05-11 2014-03-05 Becton, Dickinson and Company Verfahren zur proteinextraktion aus zellen
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8916342B2 (en) * 2006-11-13 2014-12-23 Oncohealth Corp. Identification of high grade or ≧ CIN2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (HPV) and HPV-associated cancers
CA3167595A1 (en) * 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
AU2015213420B2 (en) * 2007-05-31 2017-02-16 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
WO2009002159A2 (en) 2007-05-31 2008-12-31 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal hpv peptide vaccination
US7838215B2 (en) * 2007-09-25 2010-11-23 Canvir, Inc. Advanced cervical cell screening methods
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
CN102498217A (zh) * 2009-04-20 2012-06-13 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
TWI497075B (zh) * 2009-06-11 2015-08-21 Oncohealth Corp 早期及晚期人類乳突病毒感染之偵測
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
WO2012135666A1 (en) * 2011-04-01 2012-10-04 University Of Louisiana At Monroe Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
JP6514190B2 (ja) 2013-05-06 2019-05-15 バイオ−ラッド ラボラトリーズ インコーポレーティッド 参照物質における不安定な被分析物の安定化
EP3015863A1 (de) * 2014-10-31 2016-05-04 Mikrogen GmbH Immunologischer Test zum Nachweis von E7-Onkoproteinen in biologischen Proben
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
JP2021511054A (ja) * 2018-01-24 2021-05-06 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｈｐｖ免疫療法
BR112020019313A2 (pt) 2018-04-05 2021-01-05 Juno Therapeutics Inc Receptores de células t e células modificadas que expressam os mesmos
CN112423783A (zh) * 2018-05-30 2021-02-26 德国癌症研究中心 组合的预防性和治疗性疫苗
CN115925888B (zh) * 2022-11-26 2023-06-27 山西省中医药研究院（山西省中医院） 与人乳头瘤病毒hpv特异性结合的羊驼源纳米抗体及其应用
WO2024127321A1 (en) * 2022-12-14 2024-06-20 Ustav Jr Mart Engineered virus-like-particles for targeted capture of membrane proteins

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
EP0146654A3 (de) 1980-06-20 1986-08-20 Unilever Plc Verfahren und Vorrichtung zur Durchführung von spezifischen Bindungstesten
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5876922A (en) 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
FR2586428B1 (fr) 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
AU615159B2 (en) 1986-03-21 1991-09-26 F. Hoffmann-La Roche Ltd Determined dna sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5204061A (en) 1987-10-08 1993-04-20 Becton, Dickinson And Company Depositing a binder on a solid support
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
CA2049287C (en) 1989-03-21 2005-03-29 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5814460A (en) * 1990-02-14 1998-09-29 Diatide, Inc. Method for generating and screening useful peptides
DE4015044A1 (de) 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
US5753233A (en) 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
FR2670797A1 (fr) 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
PT523391E (pt) * 1991-07-13 2003-08-29 Dade Behring Marburg Gmbh Utilizacao dos peptidos derivados dos genes hpv-16 e6 e e7 para fins de diagnostico
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5571680A (en) 1994-01-21 1996-11-05 Beckman Instruments, Inc. Homogeneous immunoassays and enzyme based assays of analytes using capillary electrophoresis
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US5643752A (en) 1996-01-18 1997-07-01 Incyte Pharmaceuticals, Inc. Tissue inhibitor of metalloproteinases
EE9800257A (et) 1996-02-22 1999-02-15 Merck & Co., Inc. Sünteetilised HIV geenid
EP0912607A2 (de) 1996-06-21 1999-05-06 Merck & Co., Inc. Synthetische gene anthaltetnd vakzine
CA2280195A1 (en) 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US6492143B1 (en) 1998-12-17 2002-12-10 The John Hopkins University Olfactory receptor expression libraries and methods of making and using them
DE19901008A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
JP2002534971A (ja) 1999-01-25 2002-10-22 エール ユニヴァーシティ ショウジョウバエの新規な匂い物質受容体
ATE409704T1 (de) 1999-02-25 2008-10-15 Univ Columbia Gene, welche für geruchsrezeptoren aus insekten kodieren und deren anwendungen
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
US6242266B1 (en) 1999-04-30 2001-06-05 Agilent Technologies Inc. Preparation of biopolymer arrays
WO2003014303A2 (en) 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells
AU764158B2 (en) 1999-07-20 2003-08-14 Regents Of The University Of California, The Odorant receptors
US6440696B1 (en) 1999-07-28 2002-08-27 New England Medical Center E6 targeted protein (E6TP1)
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
AU2001277986A1 (en) 2000-07-25 2002-02-05 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
US6346416B1 (en) 2000-08-29 2002-02-12 Isis Pharmaceuticals, Inc. Antisense inhibition of HPK/GCK-like kinase expression
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
US20040229298A1 (en) * 2000-11-11 2004-11-18 Lu Peter S. Methods and compositions for treating cervical cancer
US7312041B2 (en) 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
ES2284559T3 (es) 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
EP1425039A4 (de) * 2001-03-23 2005-02-02 Us Gov Health & Human Serv Peptide, die mit dem humanen papillomavirus eine immunreaktion geben
TWI229132B (en) * 2001-05-04 2005-03-11 King Car Food Ind Co Ltd Method and detector for identifying subtypes of human papilloma viruses
EP1427443A4 (de) 2001-08-23 2006-03-08 Merck & Co Inc Vakzine mit papilloma-virus-e-proteinen, die durch einen viralen vektor abgegeben werden
BR0314155A (pt) 2002-09-09 2005-07-05 Arbor Vita Corp Métodos para diagnosticar câncer cervical
ATE554106T1 (de) * 2003-12-23 2012-05-15 Arbor Vita Corp Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
US20130017572A1 (en) 2009-04-30 2013-01-17 Lu Peter S Codon modified polynucleotide sequences for enhanced expression in a host system

Also Published As

Publication number Publication date
US9611315B2 (en) 2017-04-04
US20120164629A1 (en) 2012-06-28
CA2551560A1 (en) 2005-07-14
AU2004308964A1 (en) 2005-07-14
EP1708745A1 (de) 2006-10-11
EP1708745B1 (de) 2012-04-18
EP1708745A4 (de) 2007-12-19
US20100209904A1 (en) 2010-08-19
WO2005063286A1 (en) 2005-07-14
JP5030594B2 (ja) 2012-09-19
AU2004308964B2 (en) 2010-09-16
US20150093742A1 (en) 2015-04-02
US7399467B2 (en) 2008-07-15
US20050142541A1 (en) 2005-06-30
JP2007522108A (ja) 2007-08-09
US20090047660A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
DE50204883D1 (de) Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
ATE540319T1 (de) Verfahren für die bestimmung von fk506
CA2480466A1 (en) Detection and/or monitoring of synuclein-related diseases
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
DE69939121D1 (de) Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE529533T1 (de) Verfahren zum nachweis von analyten in einer probe
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE392621T1 (de) Verfahren zur quantifizierung von glykiertem protein
ATE547161T1 (de) Verfahren zur quantitativen bestimmung von poloxameren
DE602005015627D1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
ATE288589T1 (de) Verfahren zur analyse von proteinen
ATE433463T1 (de) Monospezifische antikörper gegen fibrinogen und fibrinopeptide b
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
DE602004011228D1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper